Company: BLRX
Filing Date: 2025-01-07
Form Type: 424B5
Source: 0001178913-25-000045
Chunk: 0

Company: BioLineRx Ltd.
Filing Date: 2025-01-07
Form: 424B5
Chunk 0
---
Filed Pursuant to Rule 424(b)(5) Registration No. 333-276323 PROSPECTUS SUPPLEMENT (To prospectus dated January 5, 2024) 34,332,122 American Depositary Shares Representing 514,981,830 Ordinary Shares Pre-Funded Warrants to Purchase 15,667,878 American Depositary Shares Representing 235,018,170 Ordinary Shares Warrants to Purchase 50,000,000 American Depositary Shares Representing 750,000,000 Ordinary Shares Placement Agent Warrants to Purchase 2,500,000 American Depositary Shares Representing 37,500,000 Ordinary Shares Up to 68,167,878 American Depositary Shares Representing up to 1,022,518,170 Ordinary Shares underlying the Pre-Funded Warrants, Warrants and Placement Agent Warrants We are offering 34,332,122 American Depositary Shares, or ADSs, representing 514,981,830 of our ordinary shares, to certain institutional investors pursuant to this prospectus supplement and accompanying prospectus. Each ADS represents 15 of our ordinary shares, par value NIS 0.10 per share. The purchase price of each ADS is $0.20. We are also offering pre-funded warrants, or the pre-funded warrants, to purchase up to an aggregate of 15,667,878 ADSs, representing up to 235,018,170 of our ordinary shares, to the institutional investors pursuant to this prospectus supplement and the accompanying prospectus. The purchase price of each pre-funded warrant is $0.1999. The pre-funded warrants will have an exercise price per ADS equal to $0.0001, are immediately exercisable and may be exercised at any time (subject to the beneficial ownership limitation) until all of the pre-funded warrants are exercised in full. Each ADS and pre-funded warrant is being offered together with one warrant to purchase one ADSs. Each warrant has an exercise price of $0.20 per ADS and will expire on the fifth anniversary of the original issuance date. A holder of pre-funded warrants and warrants will not have the right to exercise any portion of its pre-funded warrants and warrants if the holder (together with such holder’s affiliates, and any persons acting as a group together with such holder or any of such holder’s affiliates or any other persons whose beneficial ownership of ADSs or ordinary shares would be aggregated with the holder’s or any of the holder’s affiliates), would beneficially own ordinary shares